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Acute kidney insufficiency (AKI) occurs frequently in intensive care units (ICU). In the management of vascular
access for renal replacement therapy (RRT), several factors need to be taken into consideration to achieve an
optimal RRT dose and to limit complications. In the medium and long term, some individuals may become chronic
dialysis patients and so preserving the vascular network is of major importance. Few studies have focused on the
use of dialysis catheters (DC) in ICUs, and clinical practice is driven by the knowledge and management of
long-term dialysis catheter in chronic dialysis patients and of central venous catheter in ICU patients. This review
describes the appropriate use and management of DCs required to obtain an accurate RRT dose and to reduce
mechanical and infectious complications in the ICU setting. To deliver the best RRT dose, the length and diameter
of the catheter need to be sufficient. In patients on intermittent hemodialysis, the right internal jugular insertion is
associated with a higher delivered dialysis dose if the prescribed extracorporeal blood flow is higher than 200 ml/min.
To prevent DC colonization, the physician has to be vigilant for the jugular position when BMI < 24 and the femoral
position when BMI > 28. Subclavian sites should be excluded. Ultrasound guidance should be used especially in
jugular sites. Antibiotic-impregnated dialysis catheters and antibiotic locks are not recommended in routine practice.
The efficacy of ethanol and citrate locks has yet to be demonstrated. Hygiene procedures must be respected during
DC insertion and manipulation.
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Introduction
Acute kidney insufficiency (AKI) [1] requiring renal re-
placement therapy (RRT) occurs in approximately 4% of
critically ill patients [2] and is associated with a mortality
rate ranging between 38% and 82% [3]. Whereas vascu-
lar access is necessary for extracorporeal blood circula-
tion during RRT, measures should be taken to preserve
the vascular network, due to the higher risk of long-
term chronic renal disease in these patients [4]. In critic-
ally ill patients, veno-venous access via dialysis catheters
(DCs) rather than arteriovenous access is recommended
[5]. Most information and recommendations on tempor-
ary DC insertion and management are based on data* Correspondence: nmrozek@chu-clermontferrand.fr
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in any medium, provided the original work is pconcerning the use of long-term DCs in patients with
end-stage renal disease (ESRD) or that of central venous
catheters (CVCs) in the intensive care unit (ICU).
Whether such data may be extrapolated to DCs in critic-
ally ill patients is questionable, because critically ill
patients differ widely from ESRD patients, DCs differ
widely from CVCs with regard to manipulation and
management, and RRT techniques differ widely between
the dialysis unit and the ICU.
During the past decade, several reports have been pub-
lished on the epidemiology of DC-related complications
in ICU patients [6-15]. This review looks at the basic
characteristics of dysfunction, thrombosis, and infections
encountered with DC use in adult critically ill patients.DC dysfunction and thrombosis
DC dysfunction
Blood flow (QB) through the DC is a major determinant
of an optimal RRT dose [16]. The impact of DC on the
actual delivered dose is greater in intermittent than inan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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QB and therefore are less dependent on DC perform-
ance. In chronic hemodialysis patients, DC dysfunction
is defined as the failure to attain a sufficient extracorpor-
eal blood flow of ≥300 mL/minute with a prepump ar-
terial pressure below −250 mmHg [17]. In critically ill
patients, there are numerous definitions of DC dysfunc-
tion, most of which apply to patients on intermittent
hemodialysis [18-20]. In these studies, DC dysfunction is
defined as the inability to attain and maintain blood
flows of at least 150 ml/min [18], a low blood flow (<200
mL/min) incapable of providing adequate dialysis [19],
and QB reduction >20% despite attempts to restore pa-
tency [20]. In a recent study, DC dysfunction in patients
on continuous RRT was defined by the necessity to re-
place the DC because of an inability to attain an ad-
equate QB through the DC [11]. In clinical practice,
temporary DC dysfunction can be defined as the failure
to attain and maintain QB through the DC sufficient for
the administration of an adequate RRT dose. DC dys-
function can be diagnosed as frequent arterial and ven-
ous pressure alarms, which reveal a high negative
outflow pressure and an increase in venous pressure. DC
dysfunction can be indicated by low values of urea re-
duction in patients on continuous or intermittent RRT
techniques [21] or by low Kt/V values in patients on
intermittent hemodialysis [22]. In the latter, the deliv-
ered RRT dose can be easily estimated by ionic dialy-
sance measurement [23]. The RRT dose should be
prescribed before each session of RRT and the actual
delivered dose regularly assessed. In the VA/NIH study,
there were no differences in outcome between patients
receiving a weekly 3.9 Kt/V and a weekly 7.8 Kt/V [24].
It is therefore recommended to deliver a Kt/V of 3.9 per
week [5]. In continuous RRT, the VA/NIH study and the
RENAL study showed no differences in mortality be-
tween doses of 20 ml/kg/h and 35 ml/kg/h nor between
25 ml/kg/h and 40 ml/kg/h [24,25]. In continuous RRT,
it is recommended to deliver an effluent volume of
20–25 ml/kg/h [5]. Immediate or early DC dysfunction
usually results from improper catheter placement, such
as insertion in the wrong vessel, malposition of the cath-
eter tip (sucking the wall of the vein), and kinking of the
catheter, and strictures caused by ligatures or fascia. In-
adequate QB that occurs late after DC insertion more
often is caused by thrombotic problems, either intrinsic
(partial or total obstructive thrombosis of the catheter
lumen) or extrinsic (thrombosis or stenosis of the can-
nulated vein) catheter thrombosis [4].
In the literature, the rates of DC dysfunction differ be-
cause of differences in study design and the definitions
of dysfunction. In one survey of 73 DCs, the DC dys-
function rate was 31.5% [18]. In the Cathedia study,
when only the first DC placement was assessed, the rateof DC dysfunction was 10.7% (74/690) [11] but increased
to 24.2% (65/268) in the 134 patients with two consecu-
tive DCs inserted at an alternative site. The rate of DC
dysfunction increases with DC placement duration and
is higher beyond the first week of DC insertion [18].
However, most DC dysfunctions occur within the first
10 days of DC placement [11].
Preventive strategies of DC dysfunction include ultra-
sound guidance for a higher chance of DC placement [5],
checking for adequate flow immediately after placement,
flushing each DC lumen with saline at the beginning and
end of each RRT session, anticoagulant locking followed
by careful clamp closing, and checking the correct pos-
ition with x-rays. In a recent, prospective, randomized,
monocentric study involving 78 patients in a surgical ICU,
citrate catheter lock solution, by comparison with serum
saline lock solution, reduced DC dysfunction and
extended DC life span [20]. When dealing with DC dys-
function, classical measures to improve QB include reposi-
tioning the patient, flushing the DC with saline, rotating
the DC, and reversing the lines. In hemodynamically
stable patients with low KT/V values and persistent low
QB (QB <200 ml/min) in the extracorporeal circuit despite
implementation of the above measures, the question of
DC replacement should be addressed.
Materials of the catheter
Temporary DCs are usually made of thermoplastic elas-
tomers that are rigid at room temperature to facilitate
insertion and that soften at body temperature to
minimize vessel lesions. Silicon DCs are less thrombo-
genic than polyurethane DCs [26,27]. For an equal outer
diameter, polyurethane DCs have thinner walls than sili-
cone DCs and provide less resistance to QB. Catheter in-
tegrity may be altered by antiseptic solutions. Polyvidone
iodine has no impact on polyurethane but induces a
structural degradation of silicone. Ethanol exposure has
only a marginal impact on silicone DC integrity; in con-
trast, prolonged exposure of polyurethane DCs to con-
centrated ethanol should be avoided [28].
Because DCs are thrombogenic, manufacturers have
designed DCs coated with heparin. In chronic dialysis
patients, heparin-coated catheters are safe but do not re-
duce catheter dysfunction [29-31]. There are no pub-
lished, clinical studies in adult critically ill patients that
compare DC dysfunction rates for heparin-coated and
noncoated DCs.
Tunneled DCs
One prospective study compared tunneled and non-
tunneled DCs inserted at the femoral site in 30 critically ill
patients and showed that in patients with tunneled DCs,
DC dysfunction occurred less frequently, and the deliv-
ered RRT dose and catheter duration were higher [9].
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longer and resulted in more femoral hematomas [9].
DC lumens
Venovenous catheterization can be performed with two
single-lumen DCs either placed side by side in the same
vein or in two different veins, and with a dual-lumen
DC or a triple-lumen DC that has a third lumen for fluid
and medication administration or blood sampling. In a
retrospective study performed in critically ill patients on
intermittent hemodialysis involving 534 DCs, the inci-
dence rate of thrombotic complications was significantly
higher in dual-lumen than in single-lumen DCs [19]. In
most cases, the higher incidence rate of dual-lumen
thrombotic complications was due to thrombosis of the
arterial line.
Several internal configuration lumens are available for
dual-lumen DCs, including double D, double C, coaxial,
and shotgun lumens. Semirigid polyurethane dual-lumen
DCs with shotgun lumens and no side holes are the
most popular devices because of their ease of insertion
and good flow characteristics [32].
Distal ports of DCs, positioning and length of the catheter
The adequacy of the delivered RRT dose decreases
proportionally with the increase in blood recirculation.
Blood recirculation occurs when dialyzed blood returning
through the venous DC lumen reenters the extracorporeal
circuit through the arterial lumen, rather than returning
to the systemic circulation. Several mechanisms contrib-
ute to blood recirculation, such as Foucault current due to
turbulent flow and catheter tip clotting, obstruction flow
in the vein, reversal of flow in the central venous system
during the atrial systole (normal pulsatile flow, tricuspid
regurgitation), sheathing of the catheter with fibrin, which
can create a pathway from the outflow to the inflow port,
positive pressure ventilation, and reversal of the outflow
and inflow lines. Blood recirculation is minimized when
the venous outlet is positioned in a large central vein with
a high blood flow rate and therefore depends on the
length of DCs. Because blood recirculation depends
mainly on the ratio of the flow in the catheter and in the
vessel in which it is located, its impact on the delivered
RRT dose is lesser in continuous RRT, which uses lower
QB than intermittent hemodialysis.
The tips of DCs inserted in the upper body have to be
placed close to the right atrium to provide a better QB.
Because polyurethane DCs are made of rigid plastic, they
must not be extended beyond the superior vena cava to
avoid right atrial trauma. For internal jugular access,
both 15–20-cm silicone DCs targeting the superior vena
cava and 20–24-cm soft silicone DCs targeting the right
atrium appeared to be safe in critically ill patients. How-
ever, the silicone DCs with right atrial placement alsoimproved dialyzer life span [33]. For femoral access, DC
tips should be placed in the inferior vena cava to
minimize blood recirculation because the lower flow in
the smaller veins can dip below the pumped flow. Fem-
oral catheters <20 cm have significantly greater blood re-
circulation than those >20 cm [34]. In critically ill
patients, DCs with a minimal length of 24 cm could pos-
sibly be used, because compared with 24-cm femoral
DC 20-cm femoral DCs are independently associated
with a diminished urea reduction ratio [11].
Insertion site
Because end-stage renal disease may complicate AKI,
subclavian access for DC placement should be proposed
as a last resort for fear of vein stenosis, which compro-
mises permanent access in critically ill patients [5]. Pro-
spective surveys of DCs in critically ill patients suggest
that internal jugular access might be preferable to fem-
oral access to minimize DC dysfunction [35] and blood
recirculation [36], and to improve RRT provision [37].
The results of recent studies contrast with these data. In
the Cathedia study, which included 750 patients from 12
different ICUs, the rate of DC dysfunction of the first
RRT vascular access was similar in the femoral (36/348,
10.3%) and the internal jugular routes (38/342, 11.1%),
and the time to DC dysfunction did not differ between
the two access sites [11]. These results were confirmed
in a subgroup analysis performed in 134 patients who
received two successive DCs at two different insertion
sites (either femoral or internal jugular) and that showed
a rate of DC dysfunction of 22.4% with femoral access
and of 26.1% with internal jugular access [13]. However,
when the sides of site insertion are compared, there is a
trend to a lower rate of DC dysfunction in the right in-
ternal jugular site (6.6%) than in the femoral sites
(10.3%). DC dysfunctions are more frequently observed
at the left internal jugular site (19.5%) than at the right
internal jugular and femoral sites [11].
Among patients starting with intermittent hemodialysis,
there is no difference in the RRT dose as evaluated by the
urea reduction ratio (URR), between femoral and internal
jugular accesses [11]. Independent factors of higher URR
in multivariate analysis were female gender, lower weight,
higher predialysis urea value, and longer session duration.
A reduced URR was associated with 20-cm DCs by com-
parison with 24-cm DCs at the femoral site. For a QB <
200 ml, there was no difference between the femoral and
the internal jugular routes. In contrast, QB > 200 ml was
associated with a higher URR when DCs were inserted at
the internal jugular site [11].
In conclusion, when considering DC dysfunctions and
the delivery RRT dose, the internal jugular and femoral
routes are equivalent. Because right internal jugular ac-
cess offers the straightest route to the superior vena cava
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for DC placement in patients treated with intermittent
hemodialysis if the prescribed QB is higher than 200 ml/
min. Ultrasonography guidance, which reduces the risk of
catheter placement failure [38-40] and of insertion-related
complications, is recommended for temporary DC place-
ment in AKI patients [5], particularly for internal jugular
access, which is more frequently associated with life-
threatening catheter-insertion complications than femoral
access [10].
DC-related thrombosis
Intraluminal DC thrombosis Strategies for the preven-
tion of intraluminal thrombosis include forcible flushing
with saline of both DC lumens to clear them of blood at
the beginning and at the end of each RRT session, anti-
coagulant interdialytic locking, and careful closing of the
clamp on the catheter after interdialytic lock instillation.
Concentrated heparin is the most popular interdialytic
anticoagulant solution used for DC locking, even though
no clinical study in critically ill patients has assessed its
efficacy and safety. A recent, prospective, randomized,
monocentric study of 78 patients in a surgical ICU sug-
gests that 46.7% sodium citrate locks reduce DC dys-
function rates and increase DC life span compared with
serum saline locks [20]. When thrombosis is limited to
the DC lumen, DC locking with fibrinolytic agents, such
as urokinase and alteplase, is effective in restoring DC
patency in chronic dialysis patients [17]. Whether this
intervention is safe in critically ill patients remains un-
known and therefore the use of fibrinolytic locks cannot
yet be recommended.
DC-associated vascular thrombosis Very few data are
available for DC-associated vascular thrombosis in critic-
ally ill patients. In the Cathedia study, the rate of symp-
tomatic deep venous thrombosis was 0.5% (4/736) and
did not differ between internal jugular and femoral DC
placement. In the two centers of the study in which the
presence of DC-associated thrombotic complications
was systematically assessed by ultrasonography, the rate
of thrombosis was 16.5% (25/151), with a trend to a
higher rate in the internal jugular arm (22.7%) than in
the femoral arm (10.5%) [10]. There are no published
reports on the management of DC thrombosis. However,
when dealing with asymptomatic or symptomatic DC-
associated vascular thrombosis in the ICU setting DC
removal is mandatory.
Guidewire exchange
In chronic dialysis patients, it is recommended to use a
guidewire for replacement of a malpositioned catheter
inducing DC dysfunction [17]. Guidewire exchange inthe event of DC dysfunction often is performed in ICU
patients, but its efficacy and adequacy have not been
assessed. Further studies are needed in the ICU setting
to determine the impact of this strategy.
Catheter management
Catheter dysfunction rates differ between ICUs [11],
suggesting that procedures, teaching and training of staff
and physicians concerning DC placement, and mainten-
ance play a major role in RRT management and
provision [41]. Procedures to prevent catheter dysfunc-
tion are given in Table 1.
DC-related infections
Since a review on the prevention of catheter related in-
fection in ICU was recently published in this journal
[42], this chapter will focus on the epidemiologic par-
ticularities, and preventive measures specifically tested
in ICU patients with DCs. The definitions of DC infec-
tions are classically extrapolated from the definitions
used for CVC infections [42]. DC colonization is defined
by a positive semiquantitative [43] or quantitative [44,45]
DC tip culture. DC-related clinical sepsis is defined by DC
colonization and resolution of clinical sepsis after DC re-
moval in the absence of any other infectious site or initi-
ation of new antibiotic therapy or both. Exit site infection
is diagnosed by the presence of pus at the insertion site.
DC-related bloodstream infection is defined as the isola-
tion of the same phenotypic microorganism from periph-
eral blood culture and from DC tip culture or by a
differential time to positivity of at least 120 minutes be-
tween blood cultures centrally drawn from DC and from a
peripheral vein, when there is no other overt source for
the bacteremia except the DC. The main trials studying
DC infection in ICU are given in Table 2.
Mechanisms and incidence of DC-related infections
In short-term catheterization, the exoluminal route is con-
sidered the main mechanism of catheter colonization. Fre-
quent manipulations during DC use may predispose the
endoluminal route to DC colonization. However, the etio-
logic organisms of short-term DC and central venous
catheters are similar whatever the insertion site. This sug-
gests that the route of colonization may not differ between
these two types of catheters [6,10].
Measures for preventing DC infections
Procedures to prevent DC infections are summarized in
Table 3.
Hygiene precautions insertion technique and general
policy No specific study has been performed on this
topic for DC management in the ICU setting, and there-
fore most available data are derived from studies on
Table 1 Prevention and management of catheter
dysfunction
Choice of the dialysis catheters
Materials Silicone or polyurethane catheter
Heparin coated catheters are not recommended
Diameters 12- to 16-French (4–5 mm)
Length For the upper sites: at least 15 cm to obtain right atrium
placement for soft DC, superior vena cava for rigid DC
For the lower sites: probably at least 24 cm
Lumens Dual lumen catheter
Two single-lumen catheters less easy to place but at
least as accurate as dual lumen catheters
Tunnelization Lower rate of DC dysfunctions but placement more
difficult
Choice of the insertion site
Femoral and right jugular sites better than left jugular
site
Right internal jugular site should be preferred in
intermittent hemodialysis if QB has to be higher than
200 ml/min
Subclavian sites to be avoided
Ultrasound guidance especially for jugular sites
Preserve vascular network
Positioning of the catheter
Upper sites Tips of the catheter placed next to the right atrium in
the superior vena cava
Check chest radiography
Lower sites Tips of the catheter placed in the inferior vena cava
During renal replacement therapy (RRT)
Flush Use saline solution flushes before and after every RRT
session
Pressure Check pressure greater than −250 mmHg on the inflow
site
Check pressure <250 mmHg on the outflow site
Lock Anticoagulant lock, i.e., heparin after every RRT
Clamp Careful clamp closing after every RRT
In case of dysfunction
Patient Try to change patient position
Flush Try to flush catheter lumens with saline solutions
Catheter Try to rotate the catheter
Lumens Try to reverse catheter lumens. Prolonged port reversal
not recommended due to recirculation which
compromises efficacy
Locks Fibrinolytic locks are not evaluated and are not yet
recommended
Dose of RRT Check previous KT/V in case of intermittent hemodialysis
session and consider catheter replacement
Education of the team
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lished recently in this journal [42]. In an observational
study performed in critically ill patients, there was no dif-
ference in the rates of catheter colonizations between
central venous and DCs when similar infection control
measures were used for insertion and maintenance [8].
Thus, as recommended for central venous catheters [46]
and dialysis catheters in end-stage renal disease patients
[47], DCs in ICU patients should be inserted using max-
imal sterile barrier precautions and be manipulated under
strict aseptic conditions. Skin antisepsis should be per-
formed with >0.5% chlorhexidine preparation with alcohol
or alcoholic-povidone iodine [46]. One study demon-
strated that ultrasound guidance before insertion in the
internal jugular vein reduces the rate of central venous
catheter-related bacteremia [48]. No study has specifically
assessed whether ultrasound guidance on DC insertion
reduces DC infections in critically ill patients. Continuous
training and competence testing of medical and nursing
staff along with assessment of compliance with preventive
measures and of feedback to health care workers should
be included in preventive strategies of DC infections [47].
Antimicrobial coating and catheter selection Regard-
ing the risk of DC infections in relation to the number
of DC lumens, only one study, which was retrospective,
has focused on this topic and reported no differences in
DC infections between patients with two single-lumen DCs
and those with double lumen DCs [19]. One randomized,
control study evaluated the impact of antimicrobial-coated
DCs in critically ill patients [49]. It included both critically
and non-critically ill patients with femoral non-tunneled
DCs. The rate of DC-related infections was significantly
lower in patients with rifampin-coated DCs compared with
standard DCs. In the group with standard DCs, of the
seven patients with infection, only one developed a DC-
related bloodstream infection as defined by both blood
cultures and catheter cultures positive for the same micro-
organism. In addition, there is a potential risk for emer-
gence of antibiotic resistance when using antibiotic-coated
DCs. As recommended for central venous catheters [46],
the use of antimicrobial-coated DCs should be limited to
units with high rates of DC infections despite the imple-
mentation of adequate preventive strategies. Whether tun-
neled DCs may be used for preventing DC infections in the
ICU setting requires additional investigation, because only
one small study, involving 30 patients, has addressed this
issue and did not provide conclusive results [9]. Initiating
RRT via tunneled DC is not yet recommended [5].
Site of insertion By contrast with long-term DCs, there
are no differences in short-term, DC-related infections
between femoral and internal jugular accesses in critic-
ally ill patients [6,8,10]. However, when patients were
Table 2 Characteristics of the main trials studying dialysis catheter infection in ICU



























CRBSI: catheter colonization and
blood culture positive for the same
organism; site infection: presence of
pus at the insertion site.


















Exit site infection: erythema,
tenderness, induration, or purulence
within 2 cm of the skin at the exit
site of the catheter; CRBSI: Same
organism isolated from a culture of
the catheter and from the blood
with clinical symptoms of infection;
in the absence of laboratory
confirmation, defervescence after
removal of a catheter may be
considered indirect evidence of
CRBSI.













Infected catheter: positive catheter
tip culture with clinical signs of
sepsis resolving within 48 hours after
catheter removal; CRBSI: same
microorganism isolated from the
catheter tip culture and from
cultured peripheral blood culture
drawn during catheter placement or
within the 24 hours following
removal of the catheter. Differential
time of positivity >2 hours.















Femoral Sherertz fever (>38°C), chills, hypotension,
skin organisms cultured from at least
one blood cultures from a peripheral
vein that was not related to infection
of another site, and antimicrobial
therapy; same organism isolated
from peripheral blood culture and
from DC tip culture (>1,000 CFU);
presence of a positive quantitative
catheter culture in a patient with
clinical signs of sepsis that
disappeared within 48 hours after
catheter removal.

















CRBSI: isolation of the same
phenotypic microorganism from
both peripheral-blood culture and
catheter-tip culture growing greater
than 10^3 CFU/mL when there was
no other source for bacteremia.




























NR CRBSI: criteria for laboratory
diagnosis of infection and clinical
signs of sepsis. Laboratory diagnosis
of infection is defined as a positive
blood culture with a strain not














Femoral NR Association of fever or chills or an
overtly purulent exit site with a
positive catheter clot or catheter
culture result
NR 6.7% 13.5 ± 9.2
(tunneled)



















catheter tip colonization plus at least
one peripheral blood culture yielding
the same species with the same
antimicrobial susceptibility as the
catheter tip within 48 hours of
catheter removal, with no other



























catheter tip colonization plus at least
one peripheral blood culture yielding
the same species with the same
antimicrobial susceptibility as the
catheter tip within 48 hours of
catheter removal, with no other














































NR exit site infection: local
inflammation with purulent
discharge and positive exit site
culture; suspected CRBSI: proven
systemic infection without any other
recognized source of infection;
confirmed CRBSI: at least one
positive blood culture from a
peripheral vein along with at least
one positive blood culture from the
catheter or positive catheter tip
culture with an identical
microorganism; possible CRBSI: at
least one positive microbiological
culture, good clinical response to
catheter removal and antibiotic



















Table 2 Characteristics of the main trials studying dialysis catheter infection in ICU (Continued)













NR CRBSI: fever (>38°C) with
concordant positive blood cultures
drawn from the catheter and a
peripheral vein or a peripheral blood
culture and a concordant exit site
culture; probable CRBSI: fever with
one positive blood culture, in the
absence of any other clinically
identifiable source of infection other
than the catheter.







TC time of catheterization; ICU intensive care unit; CAVHDF Continuous arteriovenous hemodiafiltration; CRBSI Catheter-related bloodstream infection; CFU Colony-forming unit; NR not related; Simplified Brun Buisson



















Table 3 Prevention of dialysis catheter infection
Choice of the dialysis catheter
Lumens No difference between dual lumen catheter
and two single lumen catheters placed side
by side in terms of infection
Tunnelization Not recommended for initiating RRT
Antimicrobial-coated
catheters
Use not currently recommended and
should be limited to units with high rates
of DC infections despite implementation of
adequate preventive strategies
Choice of the insertion site
No difference between femoral or jugular
sites in term of infection.
Physicians should be vigilant with femoral
site in case of high body mass index, and
with internal jugular site in case of low
body mass index
Insertion procedures
Hygiene procedure Surgical hand disinfection
Depilation Wear a long-sleeved sterile gown, sterile
gloves, and cap
Use a large sterile drape
If hairs disturb vascular puncture or dressing
occlusion




Not recommended. May be proposed for
internal jugular DC placement
During RRT
Hygiene procedure Use strict aseptic conditions for every DC
manipulation
Dressing Limit manipulation
Avoid use of dialysis catheter for perfusion






Before applying a new dressing, clean skin
with antiseptic solution, 0.5% alcoholic
chlorhexidine or alcoholic povidone iodine
Change in case of disruption or soiled
dressing
Change dressings at every dialysis
Not recommended for prevention
Local ointments Not recommended for ICU dialysis catheter
Catheter Catheter replacement not scheduled
Limit indwelling time and remove as soon
as unnecessary
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related colonization was higher at the femoral site for
patients with a body mass index >28.4 and higher at the
internal jugular site for patients with a body mass index
<24.2 [10]. Because a relationship may exist between risk
of colonization and the risk of infection [50], cliniciansshould be vigilant when the femoral site is used in
patients with high body mass index, and the internal
jugular site in patients with low body mass index.
Exit site care Because of the lack of documented evidence,
local antiseptic ointment and antiseptic- impregnated dres-
sing cannot be recommended for DC management in crit-
ically ill patients.
Systematic/prophylactic changing and catheter indwel-
ling duration The rate of DC-related colonization/infec-
tion increases with DC duration, and therefore, DCs
must be removed as soon as they are no longer needed
[6,7,12]. The risk of DC colonization increases after 10
days among patients starting continuous RRT. In con-
trast, the duration of catheterization does not influence
the daily hazard rate of DC tip colonization among
patients starting with intermittent hemodialysis [12].
Additional data are needed to recommend systematic
DC replacement every 10 days in patients treated with
continuous renal replacement therapy. More informa-
tion are needed before routine scheduled changes of DC
can be recommended. DCs should be removed as soon
as no longer needed.
Effects of RRT on catheter-related infection Continu-
ous renal replacement therapy may limit the number of
catheter manipulations but can increase the risk of
hypothermia compared with intermittent hemodialysis.
A subgroup analysis of the Cathedia cohort shows that
there are no differences between these two types of RRT
in terms of infection of vascular access [12].
Antimicrobial/other DC solution lock Antimicrobial
lock consists in instilling and maintaining an antimicro-
bial solution in the catheter lumen to limit endoluminal
biofilm formation and subsequent catheter-related blood-
stream infection. Heparin is classically used as an interdia-
lytic lock solution in chronic dialysis patients. Whether
heparin lock solutions have antimicrobial activity is
debated, because experimental studies assessing the anti-
biofilm properties of heparin have yielded conflicting
results [51-53].
Antibiotic-based lock solutions are effective in pre-
venting DC-related bloodstream infections in end-stage
renal disease patients with tunneled and cuffed CVCs
[54-57]. However, a number of issues remains concern-
ing the use of the antimicrobial lock method for the pre-
vention of DC-related infections, including the risk of
developing bacterial resistance [58], and systemic tox-
icity due to leakage of these solutions [59]. Thus, using
antibiotic locks for the prevention of catheter-related
infections of non-tunneled DCs is discouraged [5].
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studied in chronic hemodialysis patients. Taurolidine is an
antibiotic with anti-lipopolysaccharide properties that is
not used to treat systemic infections. A recent study failed
to demonstrate that 1.35% taurolidine 4% citrate lock
solution reduces DC-related bacteremia compared with
heparin [60]. The development of antibiotic-resistant
organisms may be prevented in part by using chemical-
based antimicrobial solutions, such as concentrated citrate
and methyl blue paraben. Concentrated citrate lock solu-
tion has been reported to reduce DC-related bacteremia
[61]. However, this result was not confirmed in a study
with a low baseline catheter-related bloodstream infections
rate [62]. A recent, multicenter, prospective study reported
the efficacy of a new catheter lock solution combining 7%
sodium citrate, 0.15% methylene blue, and paraben for pre-
venting DC related bloodstream infections compared with
heparin solution [63]. Concentrated ethanol instilled in the
DC lumen for a short dwell time could be an attractive
antimicrobial solution, because it acts against bacteria and
fungi and is able to eradicate biofilm [64].
Very few data are available on the use of DC anti-
microbial lock in critically ill patients. The effectiveness
of 46.7% citrate locks versus saline locks, for delaying
DC related infections, was recently suggested in a rando-
mized control study involving 78 critically ill patients [20].
However, there was a very high incidence of DC related
bloodstream infections in both the citrate (24/1,000 cath-
eter days) and the saline (30/1,000 catheter days) groups.
For instance, in a survey of 534 DCs inserted in 289 critic-
ally ill patients currently locked in the interdialytic period
with 4% or 30% trisodium citrate, the rate of DC related
bloodstream infections was 1.6/1,000 catheter days [19],
and therefore whether the results of the study of Hermite
and colleagues can be extrapolated to ICUs with lower
rate of DC-related bacteremia is questionable [20]. Al-
though some antimicrobial locks appear to be promising,
further studies are necessary before the use of antimicro-
bial lock can be recommended for preventing and/or
treating DC infections.
Guidewire exchange DC replacement over guidewire
exchange in patients with a suspicion of DC infection is
a common practice in many ICUs. A systematic review
including ICU patients with different type of catheters
suggest that compared with new-site replacement, guide-
wire exchange is associated with fewer mechanical com-
plications but with a trend toward a higher rate of
catheter colonization, regardless of whether patients have
a suspected infection [65]. In a recent study in critically ill
pediatric patients, guidewire exchange was the only identi-
fied risk factor for catheter-related bloodstream infection
[66]. Several studies suggest that catheter guidewire ex-
change in conjunction with systemic anti infectioustreatment is an acceptable way to manage mild catheter-
related infections in chronic hemodialysis patients. This
strategy, called the salvage of site approach, has a low
complication rate with no increase in bacteremia episodes
and provides similar longevity to new-site placements
[17,67-70]. In ICU patients with suspected DC infection,
there is a lack of evidence to support or discourage such a
strategy. It could be proposed as an alternative option to
DC removal in hemodynamically stable patients without
endocarditis, thrombosis, or other DC-related focus of in-
fection. In our opinion, the new DC, which has been
changed over guidewire, should be removed for a new site
placement when shock develops, or in the event of persist-
ent fever or persistent positive blood cultures. We cannot
yet say whether the new DC, which has been changed
over guidewire, should be removed if the initial DC tip
culture yielded a positive result.
Conclusions
Dialysis catheter management is a major factor in ICU
renal replacement therapy. The type of catheter and
catheterization procedures, especially the insertion site
and catheter maintenance (flushes, locks), affects the qual-
ity of RRT and the risk of catheter dysfunction. In patients
on intermittent hemodialysis, the right internal jugular in-
sertion site should be preferred to deliver the best RRT
dose, if the prescribed QB is higher than 200 ml/min. Hy-
giene procedures that are the same as for central venous
catheters are of paramount importance to limit the risk of
infection. Further studies are needed to determine the in-
dication of antimicrobial locks, such as ethanol, to prevent
DC infections. The insertion site does not influence cath-
eter infection rate except for certain subpopulations. To
prevent DC colonization, the physician has to be vigilant
for the jugular position when BMI < 24 and the femoral
position when BMI > 28. Practitioners should bear in
mind that patients with acute kidney injury are likely to
become chronic dialysis patients and that it is therefore
essential to preserve ulterior potential vascular access.
This is why the subclavian insertion site is not recom-
mended. The training of teams managing patients with
DC and the teaching procedures need to be evaluated.
Key messages
Point 1 DCs should have an outer diameter of at least
12 Fr and a length of at least 15 cm in the
jugular position to obtain right atrium
placement for soft DC, superior vena cava for
rigid DC, and probably at least 24 cm in length
in the femoral site.
Point 2 The left jugular position is associated with a
higher DC dysfunction rate. In patients on
intermittent hemodialysis, the right internal
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delivered dialysis dose if the prescribed QB is
higher than 200 ml/min. To prevent DC
colonization, the physician has to be vigilant for
the jugular position when BMI < 24 and the
femoral position when BMI > 28.
Point 3 Partial thrombosis of the catheter lumen, as
evidenced by frequent pressure alarms, leads to
a decrease in QB that reduces RRT dose. In the
event of DC dysfunction, DC replacement over
guidewire can be performed particularly if DC
dysfunction results from a malpositioned DC.
Point 4 No evidence of the efficacy of antimicrobial
lock and antimicrobial-coated DC in preventing
DC infections.
Point 5 AKI is an independent risk factor for end-stage
renal disease, and preserving ulterior potential
vascular access is essential. This is why the
subclavian insertion site is not recommended.
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